Ten patients were recruited to evaluate the efficacy and safety of abrocitinib for the treatment of lichen sclerosus (LS). All patients reported rapid control of pruritus at week 2 and achieved Investigator’s Global Assessment 0 or 1 at week 12. This study suggests that the abrocitinib could be an effective and safe treatment option for LS, based on the significant improvements seen in investigator evaluations, patient-reported outcomes and skin imaging findings.